474417-44-2Relevant academic research and scientific papers
N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF
-
Page/Page column 73, (2008/06/13)
The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof, in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.
Benzimidazoles that are useful in treating sexual dysfunction
-
, (2008/06/13)
The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction, wherein L is C1-4 alkyl;RA, RB, RC, RD, and RE, are as described in the specification;Z is selected from the group consisting of N, C and CH; andA is aryl and heteroaryl as described in the specification.
Benzimidazoles that are useful in treating sexual dysfunction
-
, (2008/06/13)
The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.
Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction
Cowart, Marlon,Latshaw, Steven P.,Bhatia, Pramila,Daanen, Jerome F.,Rohde, Jeffrey,Nelson, Sherry L.,Patel, Meena,Kolasa, Teodozyi,Nakane, Masaki,Uchic, Marie E.,Miller, Loan N.,Terranova, Marc A.,Chang, Renjie,Donnelly-Roberts, Diana L.,Namovic, Marian T.,Hollingsworth, Peter R.,Martino, Brenda R.,Lynch III, James J.,Sullivan, James P.,Hsieh, Gin C.,Moreland, Robert B.,Brioni, Jorge D.,Stewart, Andrew O.
, p. 3853 - 3864 (2007/10/03)
A new class of agents with potential utility for the treatment of erectile dysfunction has been discovered, guided by the hypothesis that selective D 4 agonists are erectogenic but devoid of the side effects typically associated with dopaminergic agents. The lead agent 2-(4-pyridin-2-ylpiperazin- 1-ylmethyl)-1H-benzimidazole (1, ABT-724) was discovered by optimization of a series of benzimidazole arylpiperazines. This highly selective D4 agonist was found to be very potent and efficacious in vivo, eliciting penile erections in rats at a dose of 0.03 μmol/kg, with a positive response rate of 77% erectile incidence. Even at high doses, it was devoid of side effects in animal models of central nervous system behaviors, emesis, or nausea. The structure-activity relationship of the parent benzimidazole series leading to 1 is described, with the detailed in vitro and in vivo profiles described. Distinctive structural features were discovered that are associated with D 4 selective agonism in this series of analogues.
Benzimidazoles that are useful in treating sexual dysfunction
-
, (2008/06/13)
The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.
Benzimidazoles that are useful in treating sexual dysfunction
-
, (2008/06/13)
The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.
Benzimidazoles that are useful in treating sexual dysfunction
-
, (2008/06/13)
The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.
